(AZE) Azelis - Ratings and Ratios
Exchange: BR • Country: Belgium • Currency: EUR • Type: Common Stock • ISIN: BE0974400328
AZE EPS (Earnings per Share)
AZE Revenue
AZE: Specialty Chemicals, Food Ingredients
Azelis Group NV is a global distributor and seller of specialty chemicals and food ingredients, catering to diverse industries such as life sciences, industrial chemicals, and advanced materials. Their product portfolio supports various applications, including personal care, pharmaceuticals, food and nutrition, and agricultural solutions. With a presence in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific, Azelis leverages its extensive geographical footprint to deliver tailored solutions to its customers.
The companys business model is built around providing specialized products and services to a broad range of industries, allowing it to capitalize on growth opportunities across multiple sectors. Azelis expertise in navigating complex supply chains and its ability to deliver high-quality products position it as a reliable partner for its customers. With a history dating back to 1996, Azelis has established itself as a significant player in the specialty chemicals distribution market.
From a technical analysis perspective, Azelis stock price has been trending below its medium to long-term moving averages, with the SMA20 and SMA50 indicating a short-term consolidation phase, while the SMA200 suggests a longer-term downtrend. The ATR indicates a relatively moderate volatility. Given the current price at 14.01 EUR, the stock is closer to its 52-week low (13.16 EUR) than its high (20.94 EUR), suggesting a potential for recovery or stabilization.
Combining the technical insights with fundamental data, Azelis market capitalization stands at 3513.43M EUR, with a P/E ratio of 18.85 and a forward P/E of 16.95, indicating a moderate valuation relative to its earnings. The Return on Equity (RoE) of 9.35% suggests a decent profitability. Considering these metrics, a forecast for Azelis could involve a potential price recovery towards the 16-17 EUR range in the short to medium term, driven by a combination of technical rebound and fundamental stability, assuming the specialty chemicals market continues to grow and the company maintains its market share.
Based on the available data, a potential trading strategy could involve monitoring the stocks price action around the 13.16 EUR level for signs of support, and considering positions as it approaches the 14.58 EUR (SMA20) and 14.75 EUR (SMA50) levels, with a longer-term target potentially around 17-18 EUR, aligned with the SMA200 and factoring in the fundamental outlook.
Additional Sources for AZE Stock
AZE Stock Overview
Market Cap in USD | 3,760m |
Sector | Basic Materials |
Industry | Specialty Chemicals |
GiC Sub-Industry | Specialty Chemicals |
IPO / Inception |
AZE Stock Ratings
Growth Rating | -62.9 |
Fundamental | 68.4 |
Dividend Rating | 50.2 |
Rel. Strength | -24.3 |
Analysts | - |
Fair Price Momentum | 11.41 EUR |
Fair Price DCF | 49.73 EUR |
AZE Dividends
Dividend Yield 12m | 1.38% |
Yield on Cost 5y | 0.79% |
Annual Growth 5y | 54.20% |
Payout Consistency | 93.8% |
Payout Ratio | 29.7% |
AZE Growth Ratios
Growth Correlation 3m | -68.1% |
Growth Correlation 12m | -38.1% |
Growth Correlation 5y | -75.7% |
CAGR 5y | -17.12% |
CAGR/Max DD 5y | -0.32 |
Sharpe Ratio 12m | -0.56 |
Alpha | -28.75 |
Beta | 0.614 |
Volatility | 34.34% |
Current Volume | 272.3k |
Average Volume 20d | 255.2k |
As of June 26, 2025, the stock is trading at EUR 13.59 with a total of 272,287 shares traded.
Over the past week, the price has changed by +3.90%, over one month by -9.34%, over three months by -24.04% and over the past year by -24.37%.
Yes, based on ValueRay´s Fundamental Analyses, Azelis (BR:AZE) is currently (June 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 68.43 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AZE is around 11.41 EUR . This means that AZE is currently overvalued and has a potential downside of -16.04%.
Azelis has no consensus analysts rating.
According to our own proprietary Forecast Model, AZE Azelis will be worth about 12.6 in June 2026. The stock is currently trading at 13.59. This means that the stock has a potential downside of -7.28%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 21.4 | 57.5% |
Analysts Target Price | - | - |
ValueRay Target Price | 12.6 | -7.3% |